WallStSmart
PTNM

Pitanium Ltd

NASDAQ: PTNM · CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS

$10.39
+0.00% today

Updated 2026-05-06

Market cap
$239.10M
P/E ratio
346.33
P/S ratio
3.62x
EPS (TTM)
$0.03
Dividend yield
52W range
$1 – $15
Volume

Pitanium Ltd (PTNM) Stock Valuation Analysis

Fair value estimate, historical valuation range, and quality signals for PTNM.

WallStSmart Verdict
Overvalued

Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.

Smart Value Score: 16 / 100
P/E (TTM)
346.3x
PEG
Margin of Safety
DCF limited for this profile
EV / EBITDA
0.0x

PTNM historical valuation range

Where current P/E sits in PTNM's own 5Y range.

Insufficient historical data for 5Y percentile analysis

PTNM intrinsic value (DCF)

DCF-based fair value estimate vs current market price.

DCF has limited applicability for PTNM

Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.

Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.

PTNM valuation signals

Quick-read green flags, caution flags, and risks based on current metrics.

!
DCF limited applicability
Company profile produces unstable DCF output. Lean on P/S, EV/Sales, and historical valuation position instead of intrinsic value for this stock.
Weak financial quality
Piotroski F-Score of 3/9 suggests deteriorating fundamentals. Valuation requires closer scrutiny.

P/E Ratio — History

Current: 346.33x

No historical P/E data available

P/S Ratio — History

Current: 3.62x

Is PTNM overvalued in 2026?

Pitanium Ltd (PTNM) currently trades at $10.39 per share with a market capitalization of $239,100,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 16/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.

The stock trades at a P/E ratio of 346.3x.

A standard DCF model does not produce reliable output for PTNM under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.

Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.

Bottom line: PTNM appears richly valued on our framework, with a Smart Value Score of 16/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.

Frequently asked questions

Is PTNM overvalued in 2026?

Based on a Smart Value Score of 16/100, PTNM appears overvalued. Current price exceeds what fundamentals currently justify.

What is PTNM's fair value?

Standard DCF is unreliable for PTNM due to its current profitability profile. Revenue-based approaches such as EV/Sales or historical P/S percentile are more informative for this stock.

What P/E ratio does PTNM trade at?

PTNM trades at a P/E of 346.3x on trailing twelve-month earnings.

Is PTNM a buy based on valuation?

WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 16/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.

How does PTNM's valuation compare to its history?

Insufficient historical valuation data exists yet for a confident percentile read on PTNM.

What is PTNM's Smart Value Score?

PTNM's Smart Value Score is 16/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.